Sun Damage to Skin Cancer Risk: Understanding Actinic Keratosis

A rough, scaly patch on sun-exposed skin that will not budge with moisturiser or scrubbing is not always just dry skin. When that patch has been in place for weeks, sits on an area that has seen years of unprotected sun, and feels slightly tender or itchy, it deserves a dermatologist's eyes, because actinic keratosis, or AK, is the skin's way of signalling that UV damage has gone past surface level.

Actinic keratosis develops when cumulative ultraviolet radiation, primarily UVB, causes mutations in the DNA of keratinocytes, the cells that make up the outer layer of the skin. These altered cells multiply in a disorganised way, producing the thickened, rough texture that characterises the condition. The lesion is confined to the epidermis at this stage, which is why it is classified as a precancerous change rather than cancer itself. Left untreated, a proportion of actinic keratoses progress to squamous cell carcinoma, a form of skin cancer. Estimates of that progression rate vary, and no individual patch comes with a label predicting its behaviour, which is precisely why clinical assessment matters.

AK typically appears as a flat or slightly raised patch, pink, red, or skin-coloured, with a rough or sandpaper-like surface. Some lesions develop a hard, wart-like crust. The surrounding skin often shows other signs of chronic sun damage: uneven pigmentation, fine lines, or broken capillaries. AK is most common on the face, scalp in people with thinning hair, ears, backs of hands, and forearms, all areas that accumulate UV exposure over decades. It is not a rash, not a fungal infection, and not a reaction to a product. Treating it as any of these, with antifungal creams, heavy emollients, or aggressive scrubbing, delays the correct diagnosis and can irritate already-compromised skin.

This condition requires clinical diagnosis. A dermatologist distinguishes AK from seborrheic keratosis, Bowen's disease, and early squamous cell carcinoma through visual examination and, when needed, a biopsy. Attempting to self-diagnose from a photograph or a symptom checklist is not adequate for a lesion in this category.

Treatment depends on the number of lesions, their location, the patient's skin type, and whether any individual patch shows features that raise concern for deeper involvement. Dermatologists use several approaches, sometimes in combination. Cryotherapy applies liquid nitrogen directly to the lesion, destroying the abnormal cells through freezing. It is fast and effective for isolated patches but leaves a temporary white mark, and darker skin tones carry a higher risk of post-treatment pigmentation change.

Topical prescription treatments, including fluorouracil cream and imiquimod, work over several weeks by targeting abnormal cells across a broader field. These are prescription-only medications, and the inflammatory response they produce, which includes redness, crusting, and peeling, is part of how they work, not a sign that something has gone wrong. Photodynamic therapy applies a photosensitising agent to the skin and then activates it with a specific wavelength of light, selectively destroying the pre-cancerous cells. It is particularly useful when lesions are widespread. Diclofenac gel, another prescription option, is used for thinner, less advanced lesions. No over-the-counter product treats actinic keratosis. Sun-protective skincare can slow further damage, but it does not reverse existing DNA-altered cells.

Risk accumulates with total lifetime UV exposure, which means people who have spent years working outdoors, lived at high altitudes, or grown up without consistent sun protection carry a higher burden. Lighter skin tones have less melanin to absorb UV and are more vulnerable, but AK is not exclusive to fair skin, it simply tends to be diagnosed later in darker skin because the visual contrast is less obvious and awareness is lower. In India, the combination of intense UV index, widespread outdoor occupational exposure, and historically limited access to dermatological care means AK is likely underdiagnosed. People who notice persistent rough patches on chronically sun-exposed areas, particularly after the age of 40, should have them assessed rather than watched and waited on indefinitely.

Treating existing lesions addresses the current problem, but the skin around them carries the same history of UV damage. Recurrence is common without consistent photoprotection. A broad-spectrum sunscreen with SPF 30 or higher, applied daily to all sun-exposed areas, is not optional after an AK diagnosis, it is part of the ongoing management. Protective clothing, hats with a brim, and avoiding peak UV hours between 10 a.m. and 4 p.m. extend what sunscreen alone cannot cover. The goal after treatment is to slow the rate at which new lesions develop in already-damaged skin, because the underlying susceptibility does not disappear once a patch is removed. Actinic keratosis is the skin's record of UV exposure it has already absorbed. Treatment clears the current entry; sun protection keeps the next one from being written too soon.